According to Guoke Hengtai's announcement, the 2026 semi-annual continuous supervision and follow-up report issued by Great Wall Securities shows that the company's revenue for the first half of 2026 was 3.164 billion yuan, a year-on-year decrease of 13.98%; net profit attributable to shareholders of listed companies was 10.7065 million yuan, a year-on-year decrease of 79.45%. In the half-year of 2026 and up to the end of June 2026, the company had no lawsuits or arbitrations with a single amount of significant standards, but the total amount of arbitration involved was high; in August 2026, the second instance ruling on the contract dispute between wholly-owned subsidiaries Guoke Hengmao and Jiemei Medical rejected the appeal and upheld the original judgment. The sponsor reminds investors to pay attention to changes in the company's performance and the risks associated with litigation and arbitration.

According to Guoke Hengtai's announcement, the 2026 semi-annual continuous supervision and follow-up report issued by Great Wall Securities shows that the company's revenue for the first half of 2026 was 3.164 billion yuan, a year-on-year decrease of 13.98%; net profit attributable to shareholders of listed companies was 10.7065 million yuan, a year-on-year decrease of 79.45%. In the half-year of 2026 and up to the end of June 2026, the company had no lawsuits or arbitrations with a single amount of significant standards, but the total amount of arbitration involved was high; in August 2026, the second instance ruling on the contract dispute between wholly-owned subsidiaries Guoke Hengmao and Jiemei Medical rejected the appeal and upheld the original judgment. The sponsor reminds investors to pay attention to changes in the company's performance and the risks associated with litigation and arbitration.